Abstract:
Provided herein is a method for detecting landing quality of an aircraft. Method steps include using an aircraft data system to determine whether a vertical speed rate is greater than a first preset value when the aircraft lands; determine whether a vertical acceleration is greater than a second preset value if the vertical speed rate is not greater than the first preset value when the aircraft lands; collect landing data; generate a landing message based on the collected landing data; store or transmit the landing message; and determine the landing quality based on the landing data in the landing message.
Abstract:
A short-circuit release is disclosed, in particular for a power circuit-breaker. In at least one embodiment, the short circuit release includes an armature and pole that are located inside a coil former and further includes a yoke plate and terminal connection that are positioned around the coil former. Arranged opposite the yoke plate is a magnetic plate resting against the terminal connection.
Abstract:
The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia.
Abstract:
The present invention relates to a method for detecting landing quality of an aircraft, comprising: determining whether a vertical speed rate is greater than a first preset value or a vertical acceleration is greater than a second value when the aircraft landing; collecting landing data; generating a landing message based on collected landing data in response to that the vertical speed rate is greater than the first preset value or the vertical acceleration is greater than the second value when the aircraft landing; storing or transmitting the landing message; and determining the landing quality of the aircraft based on the landing data in the landing message.
Abstract:
The invention allows for a reduction in the amount of salt topically applied to a food product with an oil layer on its outer surface, without adversely affecting the taste of the food product. Salt particles with a particle size greater than the thickness of the oil layer are topically applied to the food product. Because substantially all of the salt particles protrude from the oil layer, they provide a saltiness perception having no meaningful difference from the saltiness perception provided by a control salt applied at higher levels.
Abstract:
The present invention discloses a process for preparing sildenafil and its intermediates having the structures outlined below: In particular, the present invention provides a process for preparing the compound of formula (I) and its intermediates, i.e. the compounds of formula (I), (II), (III) and (IV). The compound of formula (I) is obtained from the compound of formula (II); the compound (II) is obtained from the compound of formula (III) and methylpiperazine; the compound (III) is obtained by treating the compound of formula (IV) with chlorosulfonic acid; the compound (IV) is obtained though treating the compound of formula (V) in the presence of at least one selected from POX3, PX3, PX5 and their mixtures in any ratio. The process for preparing the compound of formula (I) according to the present invention reduces the side reactions in the processes of the prior art. These improvements lead to higher yields and a better industrial applicability with easier controlling of the reaction.
Abstract:
A method and device are described for wireless network virtualization, having a workgroup bridge that implements wireless virtual interfaces for virtual machines.
Abstract:
Without battery cell balancing, voltages of multiple series-connected battery cells may quickly become out of balance, which causes some cells of the battery to deteriorate faster than others, and reduces the life cycle of the battery. Embodiments of the present invention address this problem by providing a system for balanced charging of multiple series-connected battery cells. The system includes resistors that are selectably and electrically coupled in parallel with respective battery cells via activation and deactivation of respective switches. The system also includes a control unit that is configured to determine a battery cell having a lowest voltage among the battery cells, and to activate and deactivate the switches as a function of differences in voltages between the voltage of the lowest battery cell and voltages of each of the other battery cells, thus, providing balanced charging of the multiple series-connected battery cells.
Abstract:
The present invention discloses a process for preparing sildenafil and its intermediates having the structures outlined below: In particular, the present invention provides a process for preparing the compound of formula (I) and its intermediates, i.e. the compounds of formula (I), (II), (III) and (IV). The compound of formula (I) is obtained from the compound of formula (II); the compound (II) is obtained from the compound of formula (III) and methylpiperazine; the compound (III) is obtained by treating the compound of formula (IV) with chlorosulfonic acid; the compound (IV) is obtained though treating the compound of formula (V) in the presence of at least one selected from POX3, PX3, PX5 and their mixtures in any ratio. The process for preparing the compound of formula (I) according to the present invention reduces the side reactions in the processes of the prior art. These improvements lead to higher yields and a better industrial applicability with easier controlling of the reaction.
Abstract:
The present invention relates to tetrahydroprotoberberines of the formula (I) and the physiologically acceptable salts thereof. The invention also relates to the use of the compounds of the formula (I) or pharmaceutically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with dopamine receptor ligand, such as schizophrenia.